Modelling of Cathinone–Carbon Nanotube Complexes’ Stability: Theory with a Cancer Treatment Perspective
Source abstract
Abstract
Today, cathinone and its synthetic derivatives are among the most popular narcotics in the world. Their different cytotoxic activities on humans are increasingly and rapidly being published in forensic reports and the scientific literature. New studies demonstrate that these compounds target the apoptosis of some human cancer cell lines. These results could potentially open a new perspective for cathinones’ use as potential therapeutic agents. Even so, the psychostimulant effects of these compounds require testing their activity in the form of drug delivery systems. In our work, we report on the first theoretical studies concerning the potential use of functionalised carbon nanotubes (CNTs) as carriers in the targeted transport of cathinones. Using density functional theory (DFT), we predicted cathinone–CNT interaction energies in environments with different polarity, as well as the stability of complexes in simplified models of healthy and cancer tissue. The results of the current work provide first-step insights into cathinone–CNT non-covalent complex formation in neutral and acidified environments. This study may serve as the theoretical basis for further experimental works on the possibility of using cathinone–CNT complexes in targeted anticancer therapy.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Computational Drug Discovery Methods · Carbon Nanotubes in Composites
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Faculty of Chemistry and Pharmacy, University of Opole, 48, Oleska Street, 45-052 Opole, Poland
Institute of Earth Sciences, Faculty of Natural Sciences, University of Silesia in Katowice, 41-200 Sosnowiec, Poland
Funding
University of Opole
References (100+)
Show source-provided references
1. Integrating Cancer into Crisis: A Global Vision for Action from WHO and Partners10.1016/S1470-2045(24)00522-9 ↗
2. Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries
3. Recent Progress of Supramolecular Chemotherapy Based on Host–Guest Interactions10.1002/adma.202304249 ↗
4. Improved Synergistic Anticancer Action of Quercetin and Tamoxifen Citrate Supported by an Electrospun Complex Nanostructure10.1016/j.matdes.2024.112657 ↗
5. Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance)10.1200/JCO.2014.57.0572 ↗
6. Addition of the PARP Inhibitor Veliparib plus Carboplatin or Carboplatin Alone to Standard Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer (BrighTNess): A Randomised, Phase 3 Trial10.1016/S1470-2045(18)30111-6 ↗
7. Sorafenib or Placebo plus TACE with Doxorubicin-Eluting Beads for Intermediate Stage HCC: The SPACE Trial10.1016/j.jhep.2016.01.012 ↗
8. Eryilmaz, I.E., Colakoglu Bergel, C., Arioz, B., Huriyet, N., Cecener, G., and Egeli, U. (2024). Luteolin Induces Oxidative Stress and Apoptosis via Dysregulating the Cytoprotective Nrf2-Keap1-Cul3 Redox Signaling in Metastatic Castration-Resistant Prostate Cancer Cells. Mol. Biol. Rep., 52.10.1007/s11033-024-10178-4 ↗
9. In Vitro Treatment of Triple-Negative Breast Cancer Cells with an Extract from the Coriolus Versicolor Mushroom Changes Macrophage Properties Related to Tumourigenesis
10. Chunarkar-Patil, P., Kaleem, M., Mishra, R., Ray, S., Ahmad, A., Verma, D., Bhayye, S., Dubey, R., Singh, H.N., and Kumar, S. (2024). Anticancer Drug Discovery Based on Natural Products: From Computational Approaches to Clinical Studies. Biomedicines, 12.10.3390/biomedicines12010201 ↗
11. Anticancer Mechanism of Coumarin-Based Derivatives10.1016/j.ejmech.2024.116179 ↗
12. Baicalin and Baicalein in Modulating Tumor Microenvironment for Cancer Treatment: A Comprehensive Review with Future Perspectives10.1016/j.phrs.2023.107032 ↗
13. Metals in Cancer Research: Beyond Platinum Metallodrugs10.1021/acscentsci.3c01340 ↗
14. Zahirović, A., Fetahović, S., Feizi-Dehnayebi, M., Višnjevac, A., Bešta-Gajević, R., Kozarić, A., Martić, L., Topčagić, A., and Roca, S. (2024). Dual Antimicrobial-Anticancer Potential, Hydrolysis, and DNA/BSA Binding Affinity of a Novel Water-Soluble Ruthenium-Arene Ethylenediamine Schiff Base (RAES) Organometallic. Spectrochim. Acta Part A Mol. Biomol. Spectrosc., 318.10.1016/j.saa.2024.124528 ↗
15. Targeting ROS in Cancer: Rationale and Strategies10.1038/s41573-024-00979-4 ↗
16. Targeting Immunogenic Cell Stress and Death for Cancer Therapy10.1038/s41573-024-00920-9 ↗
17. Ferroptosis in Cancer: From Molecular Mechanisms to Therapeutic Strategies10.1038/s41392-024-01769-5 ↗
18. Ultrasmall Nanoparticles Induce Ferroptosis in Nutrient-Deprived Cancer Cells and Suppress Tumour Growth10.1038/nnano.2016.164 ↗
19. Cuproptosis: A Novel Therapeutic Target for Overcoming Cancer Drug Resistance10.1016/j.drup.2023.101018 ↗
20. The Present and Future of Bispecific Antibodies for Cancer Therapy10.1038/s41573-024-00896-6 ↗
21. Myeloid-Derived Suppressor Cells in Cancer and Cancer Therapy10.1038/s41571-023-00846-y ↗
22. New Immune Cell Engagers for Cancer Immunotherapy10.1038/s41577-023-00982-7 ↗
23. Radhakrishnan, R., Wilkinson, S.T., and D’Souza, D.C. (2014). Gone to Pot—A Review of the Association between Cannabis and Psychosis. Front. Psychiatry, 5.10.3389/fpsyt.2014.00054 ↗
24. Antineoplastic Activity of Cannabinoids210.1093/jnci/55.3.597 ↗
25. Cannabinoid Derivatives Exert a Potent Anti-Myeloma Activity Both in Vitro and in Vivo10.1002/ijc.30483 ↗
26. Notaro, A., Emanuele, S., Geraci, F., D’Anneo, A., Lauricella, M., Calvaruso, G., and Giuliano, M. (2019). WIN55,212-2-Induced Expression of Mir-29b1 Favours the Suppression of Osteosarcoma Cell Migration in a SPARC-Independent Manner. Int. J. Mol. Sci., 20.10.3390/ijms20205235 ↗
27. Mechanism of Anti-Glioma Activity and in Vivo Efficacy of the Cannabinoid Ligand KM-23310.1007/s11060-012-0958-5 ↗
28. Synthetic Cannabinoids Nano-Micelles for the Management of Triple Negative Breast Cancer10.1016/j.jconrel.2018.10.030 ↗
29. Inhibitory Effect of Synthetic Cannabinoids on Cytokine Production in Rheumatoid Fibroblast-like Synoviocytes
30. Fichna, J., Bawa, M., Thakur, G.A., Tichkule, R., Makriyannis, A., McCafferty, D.-M., Sharkey, K.A., and Storr, M. (2014). Cannabinoids Alleviate Experimentally Induced Intestinal Inflammation by Acting at Central and Peripheral Receptors. PLoS ONE, 9.10.1371/journal.pone.0109115 ↗
31. Activation of Cannabinoid Receptor 2 Attenuates Synovitis and Joint Distruction in Collagen-Induced Arthritis10.1016/j.imbio.2014.12.012 ↗
32. The Activation of Cannabinoid CB2 Receptors Stimulates in Situ and in Vitro Beta-Amyloid Removal by Human Macrophages10.1016/j.brainres.2009.05.098 ↗
33. Paraquat Induces Apoptosis in Human Lymphocytes: Protective and Rescue Effects of Glucose, Cannabinoids and Insulin-like Growth Factor-110.1080/08977190801984205 ↗
34. Hu, S., Sheng, W.S., and Rock, R.B. (2013). CB2 Receptor Agonists Protect Human Dopaminergic Neurons against Damage from HIV-1 Gp120. PLoS ONE, 8.10.1371/journal.pone.0077577 ↗
35. Regulation of Bone Mass, Bone Loss and Osteoclast Activity by Cannabinoid Receptors10.1038/nm1255 ↗
36. Effects of JWH015 in Cytokine Secretion in Primary Human Keratinocytes and Fibroblasts and Its Suitability for Topical/Transdermal Delivery10.1177/1744806916688220 ↗
37. Khat in the Horn of Africa: Historical Perspectives and Current Trends10.1016/j.jep.2010.01.063 ↗
38. Kitchen Chemistry: A Scoping Review of the Diversionary Use of Pharmaceuticals for Non-Medicinal Use and Home Production of Drug Solutions10.1002/dta.1622 ↗
39. Fluoromethcathinone, a New Substance of Abuse10.1016/j.forsciint.2008.11.013 ↗
40. Identification and Analytical Characterization of Nine Synthetic Cathinone Derivatives N-Ethylhexedrone, 4-Cl-Pentedrone, 4-Cl-α-EAPP, Propylone, N-Ethylnorpentylone, 6-MeO-Bk-MDMA, α-PiHP, 4-Cl-α-PHP, and 4-F-α-PHP10.1002/dta.2136 ↗
41. Mephedrone, Compared with MDMA (Ecstasy) and Amphetamine, Rapidly Increases Both Dopamine and 5-HT Levels in Nucleus Accumbens of Awake Rats10.1111/j.1476-5381.2011.01499.x ↗
42. Cocaine-like Discriminative Stimulus Effects of Alpha-Pyrrolidinovalerophenone, Methcathinone and Their 3,4-Methylenedioxy or 4-Methyl Analogs in Rhesus Monkeys10.1111/adb.12399 ↗
43. Detection of Synthetic Cathinones in Seized Drugs Using Surface-Enhanced Raman Spectroscopy (SERS)10.1016/j.forc.2024.100613 ↗
44. The Use of Bupropion SR in Cigarette Smoking Cessation10.2147/COPD.S1121 ↗
45. 15 Years of Clinical Experience With Bupropion HCl: From Bupropion to Bupropion SR to Bupropion XL
46. A Controlled Evaluation of Pyrovalerone in Chronically Fatigued Volunteers10.1159/000467975 ↗
47. Diethylpropion in the Treatment of “Refractory” Obesity10.1136/bmj.1.5231.1009 ↗
48. Khat Promotes Human Breast Cancer MDA-MB-231 Cell Apoptosis via Mitochondria and MAPK-Associated Pathways10.3892/ol.2017.6708 ↗
49. Structure-Cytotoxicity Relationship Profile of 13 Synthetic Cathinones in Differentiated Human SH-SY5Y Neuronal Cells10.1016/j.neuro.2019.08.009 ↗
50. Adverse Outcome Pathways Induced by 3,4-Dimethylmethcathinone and 4-Methylmethcathinone in Differentiated Human SH-SY5Y Neuronal Cells10.1007/s00204-020-02761-y ↗
51. Paškan, M., Rimpelová, S., Svobodová Pavlíčková, V., Spálovská, D., Setnička, V., Kuchař, M., and Kohout, M. (2022). 4-Isobutylmethcathinone—A Novel Synthetic Cathinone with High In Vitro Cytotoxicity and Strong Receptor Binding Preference of Enantiomers. Pharmaceuticals, 15.10.3390/ph15121495 ↗
52. α-Pyrrolidinononanophenone Provokes Apoptosis of Neuronal Cells through Alterations in Antioxidant Properties10.1016/j.tox.2017.05.017 ↗
53. S-(+)-Pentedrone and R-(+)-Methylone as the Most Oxidative and Cytotoxic Enantiomers to Dopaminergic SH-SY5Y Cells: Role of MRP1 and P-Gp in Cathinones Enantioselectivity10.1016/j.taap.2021.115442 ↗
54. Neurotoxicity of β-Keto Amphetamines: Deathly Mechanisms Elicited by Methylone and MDPV in Human Dopaminergic SH-SY5Y Cells10.1021/acschemneuro.6b00421 ↗
55. Leong, H.S., Philp, M., Simone, M., Witting, P.K., and Fu, S. (2020). Synthetic Cathinones Induce Cell Death in Dopaminergic SH-SY5Y Cells via Stimulating Mitochondrial Dysfunction. Int. J. Mol. Sci., 21.10.3390/ijms21041370 ↗
56. Methylone and MDPV Activate Autophagy in Human Dopaminergic SH-SY5Y Cells: A New Insight into the Context of β-Keto Amphetamines-Related Neurotoxicity10.1007/s00204-017-1984-z ↗
57. Protective Effect of Aldo–Keto Reductase 1B1 Against Neuronal Cell Damage Elicited by 4′-Fluoro-α-Pyrrolidinononanophenone10.1007/s12640-021-00380-8 ↗
58. 4′-Fluoropyrrolidinononanophenone Elicits Neuronal Cell Apoptosis through Elevating Production of Reactive Oxygen and Nitrogen Species10.1007/s11419-020-00550-x ↗
59. 4′-Iodo-α-Pyrrolidinononanophenone Provokes Differentiated SH-SY5Y Cell Apoptosis Through Downregulating Nitric Oxide Production and Bcl-2 Expression10.1007/s12640-022-00546-y ↗
60. α-Pyrrolidinophenones: A New Wave of Designer Cathinones10.1007/s11419-016-0353-6 ↗
61. Cytotoxicity of α-Pyrrolidinophenones: An Impact of α-Aliphatic Side-Chain Length and Changes in the Plasma Membrane Fluidity10.1007/s12640-018-9923-1 ↗
62. Zhou, X., Bouitbir, J., Liechti, M.E., Krähenbühl, S., and Mancuso, R.V. (2020). Para-Halogenation of Amphetamine and Methcathinone Increases the Mitochondrial Toxicity in Undifferentiated and Differentiated SH-SY5Y Cells. Int. J. Mol. Sci., 21.10.3390/ijms21082841 ↗
63. Structure–Activity Relationship of N-Ethyl-Hexedrone Analogues: Role of the α-Carbon Side-Chain Length in the Mechanism of Action, Cytotoxicity, and Behavioral Effects in Mice10.1021/acschemneuro.2c00772 ↗
64. Marszalek-Grabska, M., Lemieszek, M.K., Chojnacki, M., Winiarczyk, S., Jakubowicz-Gil, J., Zarzyka, B., Pawelec, J., Kotlinska, J.H., Rzeski, W., and Turski, W.A. (2025). Cell-Specific Vulnerability of Human Glioblastoma and Astrocytoma Cells to Mephedrone—An In Vitro Study. Molecules, 30.10.3390/molecules30112277 ↗
65. Binge-like Mephedrone Treatment Induces Memory Impairment Concomitant with Brain Kynurenic Acid Reduction in Mice10.1016/j.taap.2022.116216 ↗
66. Keto Amphetamine Toxicity—Focus on the Redox Reactivity of the Cathinone Designer Drug Mephedrone10.1093/toxsci/kfu108 ↗
67. The Effect of Mephedrone on Human Neuroblastoma and Astrocytoma Cells10.1016/j.jsps.2024.102011 ↗
68. One-Pot Synthesis of Metal–Organic Frameworks with Encapsulated Target Molecules and Their Applications for Controlled Drug Delivery10.1021/jacs.5b11720 ↗
69. ROS-Responsive Polyprodrug Nanoparticles for Triggered Drug Delivery and Effective Cancer Therapy10.1002/adma.201700141 ↗
70. Development of Exosome-Encapsulated Paclitaxel to Overcome MDR in Cancer Cells10.1016/j.nano.2015.10.012 ↗
71. Bioconjugated Manganese Dioxide Nanoparticles Enhance Chemotherapy Response by Priming Tumor-Associated Macrophages toward M1-like Phenotype and Attenuating Tumor Hypoxia10.1021/acsnano.5b06779 ↗
72. Exosome Delivered Anticancer Drugs Across the Blood-Brain Barrier for Brain Cancer Therapy in Danio Rerio10.1007/s11095-014-1593-y ↗
73. Enzyme-Activatable Polymer–Drug Conjugate Augments Tumour Penetration and Treatment Efficacy10.1038/s41565-019-0485-z ↗
74. Blood–Brain-Barrier-Penetrating Albumin Nanoparticles for Biomimetic Drug Delivery via Albumin-Binding Protein Pathways for Antiglioma Therapy10.1021/acsnano.6b04268 ↗
75. Tumor-Selective Catalytic Nanomedicine by Nanocatalyst Delivery10.1038/s41467-017-00424-8 ↗
76. Novel Concept of the Smart NIR-Light–Controlled Drug Release of Black Phosphorus Nanostructure for Cancer Therapy10.1073/pnas.1714421115 ↗
77. TLR7/8-Agonist-Loaded Nanoparticles Promote the Polarization of Tumour-Associated Macrophages to Enhance Cancer Immunotherapy10.1038/s41551-018-0236-8 ↗
78. Imidazole Ketone Erastin Induces Ferroptosis and Slows Tumor Growth in a Mouse Lymphoma Model10.1016/j.chembiol.2019.01.008 ↗
79. Liu, M., Zhang, Z., Wang, J., Guo, R., Zhang, L., Kong, L., Yu, Y., Zang, J., Liu, Y., and Li, X. (2025). Immunomodulatory and Anti-Ovarian Cancer Effects of Novel Astragalus Polysaccharide Micelles Loaded with Podophyllotoxin. Int. J. Biol. Macromol., 290.10.1016/j.ijbiomac.2024.138960 ↗
80. do N.; Pereira, A.C.M.V.; Rocha, J.V.R.; Alves, C. dos S.C.; Almeida, J.R.G. da S.; Gomes, A.S.L.; Bakuzis, A.F.; Junior, S.A. Design of a Magnetic Nanocarrier Containing Phyllacanthone as Delivery of Anticancer Phytochemical: Characterization and Theranostic in Vitro Applications10.1016/j.jallcom.2024.177860 ↗
81. Transforming Bone Cancer Treatment: A Comprehensive Review of Green-Synthesized Metal Nanoparticles10.1186/s12935-025-03827-6 ↗
82. Functionalized Carbon Nanotubes for Delivery of Ferulic Acid and Diosgenin Anticancer Natural Agents10.1021/acsabm.3c00700 ↗
83. Singh, G., Nenavathu, B.P., Imtiyaz, K., and Moshahid A Rizvi, M. (2020). Fabrication of Chlorambucil Loaded Graphene- Oxide Nanocarrier and Its Application for Improved Antitumor Activity. Biomed. Pharmacother., 129.10.1016/j.biopha.2020.110443 ↗
84. Madeo, L.F., Schirmer, C., Cirillo, G., Asha, A.N., Ghunaim, R., Froeschke, S., Wolf, D., Curcio, M., Tucci, P., and Iemma, F. (2024). ZnO–Graphene Oxide Nanocomposite for Paclitaxel Delivery and Enhanced Toxicity in Breast Cancer Cells. Molecules, 29.10.3390/molecules29163770 ↗
85. Biomedical Applications of Carbon Nanotubes: A Systematic Review of Data and Clinical Trials10.1016/j.jddst.2024.105932 ↗
86. Soluble Single-Walled Carbon Nanotubes as Longboat Delivery Systems for Platinum(IV) Anticancer Drug Design10.1021/ja073231f ↗
87. Combined Adsorption and Covalent Linking of Paclitaxel on Functionalized Nano-Graphene Oxide for Inhibiting Cancer Cells10.1021/acsomega.7b02022 ↗
88. Pectin-Conjugated Magnetic Graphene Oxide Nanohybrid as a Novel Drug Carrier for Paclitaxel Delivery10.1080/21691401.2017.1421211 ↗
89. Cytotoxicity of Graphene Oxide and Graphene in Human Erythrocytes and Skin Fibroblasts10.1021/am200428v ↗
90. Distribution and Biocompatibility Studies of Graphene Oxide in Mice after Intravenous Administration10.1016/j.carbon.2010.11.005 ↗
91. Synthesis, Biocompatibility and Biological Activity of a Graphene Oxide-Folic Acid Conjugate for Cytarabine Delivery10.1016/j.colsurfa.2024.134360 ↗
92. The Ph Paradigm in Cancer10.1038/s41430-020-0684-6 ↗
93. MRI of the Tumor Microenvironment10.1002/jmri.10181 ↗
94. Frisch, M.J., Trucks, G.W., Schlegel, G.E., Scuseria, M.A., Robb, J.R., Cheeseman, G., Scalmani, V., Barone, G.A., Petersson, H., and Nakatsuji, X. (2019). Gaussian 16 Revision C.01 2019, Gaussian, Inc.
95. Dennington, R., Keith, T.A., and Millam, J.M. (2016). GaussView 6.0 2016, Gaussian, Inc.
96. Density-Functional Exchange-Energy Approximation with Correct Asymptotic Behavior10.1103/PhysRevA.38.3098 ↗
97. Development of the Colle-Salvetti Correlation-Energy Formula into a Functional of the Electron Density10.1103/PhysRevB.37.785 ↗
98. Results Obtained with the Correlation Energy Density Functionals of Becke and Lee, Yang and Parr10.1016/0009-2614(89)87234-3 ↗
99. Effect of the Damping Function in Dispersion Corrected Density Functional Theory10.1002/jcc.21759 ↗
100. DFT Study of Zigzag (n, 0) Single-Walled Carbon Nanotubes: 13C NMR Chemical Shifts10.1016/j.jmgm.2016.04.008 ↗